Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein N-terminal glutamine amidohydrolase (NTAQ1) is a monomeric enzyme involved in the N-end rule pathway of protein degradation. It catalyzes the deamidation of N-terminal glutamine residues to produce glutamate, a reaction necessary for subsequent arginylation, polyubiquitination, and degradation of the substrate protein. NTAQ1 has a unique alpha-beta-alpha sandwich architecture with a conserved catalytic triad (Cys-His-Asp) in its active site. The enzyme is highly specific for N-terminal glutamine and does not act on internal, C-terminal, or acetylated N-terminal glutamine residues. Its activity is central to the regulation of protein half-life in eukaryotic cells, and mutations or dysfunctions in its human or animal homologs have been linked to cancer and neurological conditions.
Enzyme inhibition (experimental): thiol-specific reagents such as iodoacetamide and N-ethylmaleimide inhibit NTAQ1 in vitro.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein N-terminal glutamine amidohydrolase (NTAQ1).